The Role of Jak2 Inhibitors in the Management of Cml: Can We Rest the Case?

Science Proceedings
doi 10.14800/sp.383
Full Text
Abstract

Available in full text

Date
Authors

Unknown

Publisher

Smart Science and Technology, LLC

Related search

The Role of Early Molecular Response in the Management of Chronic Phase CML

Current Hematologic Malignancy Reports
Cancer ResearchOncologyHematology
2017English

How Can We Improve the Management of Depression?

BMJ
2002English

JAK2 Inhibitors: Are They the Solution?

Clinical Lymphoma, Myeloma and Leukemia
Cancer ResearchOncologyHematology
2011English

Steroids for Pediatric Cardiac Surgery: Can We Put the Discussion to Rest?

Journal of Cardiothoracic and Vascular Anesthesia
Cardiovascular MedicineAnesthesiologyPain MedicineCardiology
2019English

Can We See What Is Invisible? The Role of MRI in the Evaluation and Management of Patients With Pathological Nipple Discharge

Breast Cancer Research and Treatment
Cancer ResearchOncology
2019English

Therapeutic Potential of JAK2 Inhibitors

The Journal of OncoPathology
2013English

CML in India: Are We There Yet?

Indian Journal of Hematology and Blood Transfusion
Hematology
2019English

How Can We Measure the VAT Fraud and Evasion? Case of Albania

European Journal of Economics and Business Studies
2015English

Museums for Science Education: Can We Make the Difference? The Case of the EST Project

Journal of Science Communication
Communication
2007English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy